About
AstraZeneca PLC is a British-Swedish multinational pharmaceutical and biotechnology company founded in 1999. It applies quantum computing to molecular simulations, drug-target binding calculations, and pharmaceutical R&D optimization. In June 2023, AstraZeneca partnered with SandboxAQ, an Alphabet spinoff, to use quantum-inspired AI drug discovery and development tools that reduce the time and cost of bringing treatments to the clinic. AstraZeneca uses SandboxAQ's AQ-FEP software, which combines the accuracy of quantum mechanical equations with the speed and power of AI on classical computing hardware, for treatments for cancer, Alzheimer's, Parkinson's, and other conditions. In June 2025, AstraZeneca joined a collaborative research program with IonQ, AWS, and NVIDIA to develop a quantum-accelerated computational chemistry workflow that delivered a 20x speedup in time-to-solution compared to prior benchmarks. AstraZeneca serves the global pharmaceutical market with quantum-enhanced drug discovery, computational chemistry, and AI-accelerated pharmaceutical development.
Quantum Specifications
| Quantum Focus | software |
Backed By
Application Areas
Frequently Asked Questions
Related News
AstraZeneca: The Bigger Picture Remains Solid Growth Amidst Improving Margins And Returns
AstraZeneca stock jumps after surprise trial win for lung disease drug where rivals have failed
AstraZeneca: The Big China Bet
How AstraZeneca shot for the moon — and hit
China charges former AstraZeneca executive
